Cell-based Cancer Immunotherapy

Cell-based Cancer Immunotherapy, Volume 183 provides the latest progress concerning research on anticancer cellular immunotherapies and their immunological, translation, or clinical aspects. Topics covered include Methods behind clinical DC vaccine products against glioblastoma, Fully closed and automated isolation of natural blood dendritic cells for cancer immunotherapy, Methods behind Oncolytic virus-based DC vaccines in cancer: towards a multiphase combined treatment strategy for Glioblastoma (GBM) patients, Identification of TCR repertoire patterns linked with anti-cancer immunotherapy, Training of epitope-TCR prediction models with healthy donor-derived cancer-specific T cells, Methods behind neoantigen predictions for anticancer vaccines, Methods behind CD137L-DC-EBV-VAX anticancer vaccine, and much more.

Format: Hardback
Length: 318 pages
Publication date: 05 March 2024
Publisher: Elsevier Science Publishing Co Inc

Cell-based Cancer Immunotherapy, Volume 183, presents the most recent advancements in research on anticancer cellular immunotherapies, encompassing their immunological, translational, and clinical aspects. This comprehensive volume explores a wide range of topics, including:

Clinical DC Vaccine Products Against Glioblastoma: This section delves into the methods employed to develop effective clinical DC vaccine products against glioblastoma. It discusses fully closed and automated isolation techniques for natural blood dendritic cells, which are crucial for cancer immunotherapy.

Oncolytic Virus-Based DC Vaccines in Cancer: This section explores the use of oncolytic viruses as vectors for DC vaccines in cancer treatment. It discusses the potential of these vaccines in combination with other therapies, such as chemotherapy, to enhance the efficacy of Glioblastoma (GBM) patients.

Identification of TCR Repertoire Patterns Linked with Anti-Cancer Immunotherapy: This section focuses on identifying TCR repertoire patterns associated with anti-cancer immunotherapy. It discusses the use of advanced techniques, such as next-generation sequencing, to analyze the TCR repertoire of cancer-specific T cells and predict their potential therapeutic efficacy.

Training of Epitope-TCR Prediction Models with Healthy Donor-Derived Cancer-Specific T Cells: This section explores the training of epitope-TCR prediction models using healthy donor-derived cancer-specific T cells. It discusses the development of accurate prediction models that can aid in the design of personalized anticancer vaccines.

Neoantigen Predictions for Anticancer Vaccines: This section discusses the methods employed to predict neoantigens, which are potential targets for anticancer vaccines. It explores the use of computational techniques and bioinformatics to identify novel antigens that can stimulate an immune response against cancer cells.

CD137L-DC-EBV-VAX Anticancer Vaccine: This section presents the development of a CD137L-DC-EBV-VAX anticancer vaccine. It discusses the use of dendritic cells, EBV, and VAX as vaccine components and their potential to induce immune responses against cancer cells.

Numerous other topics are covered in this volume, including:

Gold Standard Assessment of Immunogenic Cell Death Induced by Photodynamic Therapy: This section explores the assessment of immunogenic cell death induced by photodynamic therapy, a promising treatment modality for cancer. It discusses the development of in vitro to tumor mouse models and the application of anti-cancer vaccination strategies.

TCR Analyses for Colorectal Cancer-Associated TILs: This section focuses on the analysis of TCRs in colorectal cancer-associated TILs (tumor-infiltrating lymphocytes). It discusses the use of advanced techniques, such as xCELLigence, Incucyte, and/or Cr/LDH/maker-release assays, to study the immune response and therapeutic potential of TILs.

Humanized Mouse Models for Anti-Cancer Therapy: This section explores the use of humanized mouse models for anti-cancer therapy. It discusses the development of models that recapitulate the human immune system and the evaluation of novel therapeutic agents in these models.

In vitro Re-Challenge of CAR T Cells: This section discusses the in vitro re-challenge of CAR T cells, a promising treatment approach for cancer. It explores the use of engineered T cells to target specific cancer cells and the potential for long-term remission and cure.

Adoptively Transferred Tumor-Draining Lymphocytes for Anticancer Immunotherapy: This section explores the use of adoptively transferred tumor-draining lymphocytes for anticancer immunotherapy. It discusses the isolation and activation of tumor-draining lymphocytes and their potential to enhance the immune response against cancer cells.

A Murine Glioblastoma Platform to Test Cellular Therapies with the Standard of Care: This section presents a murine glioblastoma platform to test cellular therapies with the standard of care. It discusses the development of models that mimic the characteristics of human glioblastoma and the evaluation of novel therapeutic agents in these models.

Cell-based Cancer Immunotherapy, Volume 183, serves as a valuable resource for researchers, clinicians, and healthcare professionals interested in advancing the field of cellular immunotherapies for cancer treatment. It provides a comprehensive overview of the latest research, techniques, and clinical applications, enabling them to stay updated with the latest developments and make informed decisions in their work.

Weight: 450g
Dimension: 234 x 191 (mm)
ISBN-13: 9780443139956